AstraZeneca withdraws US COVID vaccine application, shifts focus to antibody treatments
Fierce Pharma
NOVEMBER 10, 2022
AstraZeneca withdraws US COVID vaccine application, shifts focus to antibody treatments. aliu. Thu, 11/10/2022 - 09:02.
Sat.Nov 05, 2022 - Fri.Nov 11, 2022
364 
Firefly, Sprinter Team Up to Close the Loop on Virtual Primary Care
MedCity News
NOVEMBER 10, 2022
Sprinter Health is integrating its at-home clinical and diagnostic services into Firefly Health’s virtual primary care model. Firefly’s members will be able to receive common medical services from Sprinter clinicians in their homes — such as vital checks, blood draws, electrocardiograms, diabetic eye exams and diabetic foot screenings.
Join 8,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
SirsiDynix CloudSource+ Now Offering Get It Now From CCC
Copyright Clearance Center
NOVEMBER 7, 2022
November 7, 2022, LEHI, Utah — CloudSource+ , the newest content solution for open access materials from SirsiDynix , has integrated with Get It Now from CCC (Copyright Clearance Center) to provide immediate purchase and delivery of full-text articles to unsubscribed journals. Get It Now is used by hundreds of academic libraries around the world to help expand their virtual collections.
Device Measures Hemoglobin More Accurately in Dark Skin
Medgadget
NOVEMBER 11, 2022
Researchers at the University of Texas at Arlington, in collaboration with Shani Biotechnologies, a local firm, have created a point-of-care device that can accurately measure hemoglobin levels and perform pulse oximetry in individuals with dark skin. At present, methods to determine hemoglobin levels at the point of care, such as pulse oximetry, are inaccurate in individuals with higher levels of melanin in their skin, and there is a clear need to develop alternatives that work for everyone.
AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Moderna’s Spikevax carries higher risk of myocarditis than Pfizer's Comirnaty, study says
Fierce Pharma
NOVEMBER 8, 2022
Moderna’s Spikevax carries higher risk of myocarditis than Pfizer's Comirnaty, study says. zbecker. Tue, 11/08/2022 - 11:03.
Report: Health Insurance Is Influencing Americans’ Job Choices
MedCity News
NOVEMBER 9, 2022
More than 31% of people with employer-sponsored insurance stuck with a job they disliked for the company’s health insurance, a Forbes Advisor survey found. Another 8% of respondents left a job they liked to seek better coverage.
Sign up to get articles personalized to your interests!
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
More Trending
A Culture of Quality: The Catalyst to Accelerate Innovation
PharmExec
NOVEMBER 8, 2022
Why enabling a shared culture of quality across an organization is key to maintaining pharma’s recent pace of innovation wins—while inspiring new levels of confidence.
GSK's CAR-T rival Blenrep fails multiple myeloma trial, endangering its accelerated approval
Fierce Pharma
NOVEMBER 7, 2022
GSK's CAR-T rival Blenrep fails multiple myeloma trial, endangering its accelerated approval. aliu. Mon, 11/07/2022 - 09:45.
What Healthcare Insights Can We Gain from Space Exploration? [Sponsored]
MedCity News
NOVEMBER 7, 2022
In an interview, the deputy director and chief innovation officer of Translational Research Institute for Space Health, headquartered at Baylor College of Medicine, described some of the group’s work, adapting known tech for space applications and using space-based insights to improve healthcare at home.
First human trials of lab-grown red blood cells start in UK
pharmaphorum
NOVEMBER 7, 2022
Blood cells grown in a laboratory have been given to people for the first time in a clinical trial being carried out by researchers in the UK, in the hope that plentiful supplies of rare blood groups can be manufactured to order. A team from the universities of Bristol and Cambridge, NHS trusts and NHS Blood and Transplant (NHSBT) have started giving small quantities of the lab-grown red blood cells – a couple of teaspoons full – to two healthy volunteers to see if they are safe.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Cyagen and Neurophth partner to develop gene therapy vectors
Pharmaceutical Technology
NOVEMBER 8, 2022
Cyagen and Neurophth Therapeutics have entered a strategic partnership to jointly develop next-generation AAV gene therapy vectors for specific kinds of genetic ophthalmic ailments. According to the deal, Cyagen will leverage its artificial intelligence (AI)-driven high-throughput platform for discovering new AAV vectors with enhanced tissue targeting expertise, tissue specificity and productivity. .
Sanofi, GSK crash the COVID-19 vaccine party late with a world-first nod for their next-gen booster
Fierce Pharma
NOVEMBER 10, 2022
Sanofi, GSK crash the COVID-19 vaccine party late with a world-first nod for their next-gen booster. fkansteiner. Thu, 11/10/2022 - 14:09.
Consumers Need Better Communication From Their Health Plans, Survey Shows
MedCity News
NOVEMBER 7, 2022
More than half, or 58%, of health plan members are “overwhelmed” when it comes to managing their health plans. Insurers need to provide information in a way that’s accessible and easy to understand, the report stated.
Digital Biomarkers Could Reshape CNS Diagnosis, Treatment
PharmExec
NOVEMBER 8, 2022
AI drives new signal-detection efforts in Alzheimer’s and ALS.
The legacy of Glen de Vries: Our last interview with the pioneering entrepreneur
PharmaVoice
NOVEMBER 11, 2022
Recorded just weeks before his passing, our sit-down interview with the legendary medical sciences entrepreneur showcased his passion for pushing the industry toward its next frontier.
Eli Lilly ordered to pay $177M to rival Teva in migraine patent fight
Fierce Pharma
NOVEMBER 10, 2022
Eli Lilly ordered to pay $177M to rival Teva in migraine patent fight. zbecker. Thu, 11/10/2022 - 11:11.
FDA Again Spurns BrainStorm’s ALS Data, This Time With Official Refusal
MedCity News
NOVEMBER 10, 2022
BrainStorm Cell Therapeutics’ stem cell therapy for amyotrophic lateral sclerosis received an FDA refuse-to-file letter, correspondence that informs a company its application seeking approval is incomplete. The notice means BrainStorm might need to run another clinical trial.
First needle-free COVID-19 vaccine patch
European Pharmaceutical Review
NOVEMBER 9, 2022
Vaxxas, a biotechnology company has announced the start of its Phase I clinical trial of a needle-free COVID-19 vaccine, delivered via a high-density microarray patch (HD-MAP), giving potential coverage of all major SARS-CoV-2 variants. The COVID-19 vaccine patch is based on HD-MAP delivery of HexaPro, a second-generation version of the spike protein used in all major US-approved COVID-19 vaccines.
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Stanford prof pays investors in defunct biotech Nuredis $29m
pharmaphorum
NOVEMBER 11, 2022
A prominent genetics professor at Stanford University in the US has paid $29 million to investors in Nuredis – a biotech that has now been wound up – after a California court found he misrepresented the company to investors. Dr Stanley Cohen was sued by Alafi Capital and the Christopher Alafi Family Trust – the only investors in Nuredis – in 2018. The lawsuit claimed he misled them whist persuading them to invest $20 million in the biotech, set up to develop a candidate therapy for neurodegenera
After beating third-quarter expectations, BioNTech strengthens sales outlook for the year
Fierce Pharma
NOVEMBER 7, 2022
After beating third-quarter expectations, BioNTech strengthens sales outlook for the year. kdunleavy. Mon, 11/07/2022 - 10:31.
Debunking Cloud Cost and ROI Hogwash for Healthcare
MedCity News
NOVEMBER 7, 2022
The hogwash started in The Wall Street Journal with a contrarian take on a recent KPMG technology report. But cloud operates in a fundamentally different paradigm from the IT infrastructure of the past, and embracing big change is rarely free or easy. But the rewards of evolving are obvious and far too great to ignore.
First patients given lab-grown blood cell transfusion
European Pharmaceutical Review
NOVEMBER 7, 2022
Lab-grown blood cells have been transfused into a second patient in the world’s first-of-a-kind clinical trial , opening up future treatments for blood disorders such as sickle cell if found safe and effective. Stem cells from blood donors were separated and grown to produce modified red blood cells at NHS Blood and Transplant ( NHSBT ) Advanced Therapies Unit in Bristol.
How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
Sanofi signs $1.2bn research alliance with AI specialist Insilico
pharmaphorum
NOVEMBER 9, 2022
Sanofi has tapped into the artificial intelligence expertise of Chinese biotech Insilico Medicine with a six-compound drug discovery collaboration that could be worth up to $1.2 billion. The alliance is backloaded, with $21.5 million paid upfront and Insilico also in line for mid-single to up to low double-digit tiered royalties for any products developed, but is comfortably the Chinese company’s largest deal to date.
Neurotech's vision loss cell therapy implant hits primary goals in phase 3 trials
Fierce Pharma
NOVEMBER 8, 2022
Neurotech's vision loss cell therapy implant hits primary goals in phase 3 trials. ntaylor. Tue, 11/08/2022 - 06:28.
Northwell, Aegis Launch Virtual Menopause Care Startup for Employers
MedCity News
NOVEMBER 10, 2022
Aegis Ventures launched a new startup with Northwell Holdings, the venture capital arm of Northwell Health. The New York City-based company, named Upliv, focuses on virtual menopause care. It will partner with employers to provide its services to their employees at no cost.
Heart failure: clinical trials update 2022
European Pharmaceutical Review
NOVEMBER 11, 2022
The American Heart Association (AHA)’s Scientific Sessions 2022 is a global exchange of the latest advancements in research and clinical practice of cardiovascular science. The recent meeting, which took place from 5-7 November, saw updates on clinical trials for treatment of acute heart failure (AHF), hypertension and other cardiac conditions. AHF is a major contributor to morbidity and mortality for heart failure patients.
How to Stay Competitive in the Evolving State of Martech
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
Can gene therapies for haemophilia defend their high price tags?
Pharmaceutical Technology
NOVEMBER 9, 2022
Despite their potential multi-million-dollar sticker price, if haemophilia treatments by BioMarin and CSL Behring prove durable, they could help patients save money compared to current treatments, experts note. On November 2, the Institute for Clinical and Economic Review (ICER) released its updated evidence aimed at measuring the clinical effectiveness and cost of the two haemophilia gene therapies.
Troubled Clovis telegraphs bankruptcy amid FDA hardball on key cancer drug, difficulty in fundraising
Fierce Pharma
NOVEMBER 9, 2022
Troubled Clovis telegraphs bankruptcy amid FDA hardball on key cancer drug, difficulty in fundraising. aliu. Wed, 11/09/2022 - 11:33.
Patient Engagement Collaboration Is an EHR’s Missing Link
MedCity News
NOVEMBER 6, 2022
Instead of EHR companies trying to build solutions in-house, collaborating with a patient engagement technology provider is the simplest and most cost-effective way for them to deliver the communication link demanded by today’s healthcare consumer.
Minoryx and Neuraxpharm team to provide new therapy for rare CNS disorders
European Pharmaceutical Review
NOVEMBER 10, 2022
Minoryx Therapeutics focused on the development of treatments for orphan central nervous system (CNS) disorders and the Neuraxpharm Group announced the completion of a strategic licence agreement. Under the agreement, Minoryx grants Neuraxpharm exclusive European rights to its lead candidate: leriglitazone. Neuraxpharm obtains exclusive rights to commercialise leriglitazone in Europe and will join with Minoryx to continue the further development of leriglitazone.
Let's personalize your content